Free Trial
OTCMKTS:HYPMY

Hypera (HYPMY) Stock Price, News & Analysis

Hypera logo
$3.13 +0.09 (+2.80%)
As of 01/30/2025 03:50 PM Eastern

About Hypera Stock (OTCMKTS:HYPMY)

Key Stats

Today's Range
$3.12
$3.16
50-Day Range
$2.65
$3.48
52-Week Range
$2.64
$7.12
Volume
10,904 shs
Average Volume
9,673 shs
Market Capitalization
$1.98 billion
P/E Ratio
N/A
Dividend Yield
4.48%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, balance, Flavonid, histamin, NeoFresh, neolefrin, Neochemistry Vitamins, Neosorum, and Torsilax brand names; and consumer health products under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.

Receive HYPMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hypera and its competitors with MarketBeat's FREE daily newsletter.

HYPMY Stock News Headlines

Hypera: Short-Term Pain For Long-Term Gain
Hypera S.A. Reports Strategic Shift Amid Revenue Decline
Free Stock Ticker Inside: This Indicator Caught Nvidia’s Rallies
I’m not one to make super bold statements… But today, I’m making an exception. Because I’m 100% convinced this is the best indicator I’ve used for trading Nvidia… Don’t believe me? Just take a look at the last two rallies: This powerful indicator caught both moves almost perfectly.
EMS offers to buy Hypera for R$30 per share, Brazil Journal reports
Hypera confirms acquisition proposal received from EMS
See More Headlines

HYPMY Stock Analysis - Frequently Asked Questions

Hypera's stock was trading at $3.06 at the beginning of 2025. Since then, HYPMY shares have increased by 2.1% and is now trading at $3.1250.
View the best growth stocks for 2025 here
.

Shares of HYPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
1/31/2025
Next Earnings (Estimated)
3/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:HYPMY
Fax
N/A
Employees
10,301
Year Founded
N/A

Profitability

Net Income
$330.61 million
Pretax Margin
18.33%

Debt

Sales & Book Value

Annual Sales
$1.59 billion
Cash Flow
$0.57 per share

Miscellaneous

Free Float
N/A
Market Cap
$1.98 billion
Optionable
Not Optionable
Beta
1.01
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

This page (OTCMKTS:HYPMY) was last updated on 1/31/2025 by MarketBeat.com Staff
From Our Partners